Accordingly, the ESMO recommendation for patients with EGFR-mutated NSCLC who progress on TKI therapy is to assess actionable mechanisms of resistance on tissue rebiopsy when possible or on circulating tumor DNA (ctDNA) when no tissue is available [98]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.